Scalper1 News
Shares of PTC Therapeutics (PTCT) initially plunged more than 20% in after-hours trading Thursday but later rose 4%, after the company said it would still submit for approval its muscular-dystrophy drug that failed a late-stage trial. PTC said patients with Duchenne muscular dystrophy (DMD) who were given its drug Translarna for 48 weeks did not show a statistically significant improvement in distance traveled over the six-minute walk test. The Scalper1 News
Scalper1 News